Johnson & Johnson reported strong Q2 2017 results, with adjusted EPS exceeding expectations and raised guidance for the year. Management expressed confidence in accelerated growth in the second half, driven by new product launches and recent acquisitions like Actelion. Overall, the positive earnings surprise and optimistic outlook are likely to have a positive short-term impact on the stock price.
[1]